Comparison of Letrozole and Mifepristone as a pretreatment in first trimester medical Abortion.

Comparison of letrzole Vs Mifepristone as pre-treatment in first trimester medical abortion : A Randomised controlled Trial - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094265

Enrollment

110

Registered

2025-09-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Mifepristone: Tab Mifepristone as Control Dose: 200 mg stat Route: oral Use:Pretreatment in Medical Termination of Pregnancy Side effects: nausea, vomitting, pain in abdomen Control I

Eligibility

Inclusion criteria

Inclusion criteria: 1.Maternal age >18yrs. 2.Women wanting medical termination of pregnancy 3.Women opting for medical termination of Pregnancy. 4.Who agreed to participate in the trial voluntarily with informed consents.

Exclusion criteria

Exclusion criteria: 1.Age below 18yrs 2.Suspected Ectopic Pregnancy 3.H/O any co-morbidities(CKD, Adrenal insufficiency, Heart, Liver disease)/ H/O of any coagulatory dysfunction/ anticoagulant drugs. 4.Abnormal Uterine Lesions(Fibroids, congenital malformations or intrauterine adhesions).

Design outcomes

Secondary

Measure	Time frame
1.To Compare the mean induction to abortion interval. 2.To Compare the no. of doses of Tab Misoprostol required. 3.To Compare the cost effectiveness of Letrozole & Mifepristone. Timepoint: comparison between the 2 after 2 weeks of assessment period	—

Primary

Measure	Time frame
To Compare efficacy of Letrozole & Mifepristone as pretreatment in First Trimester Medical Abortions. Timepoint: Comparison between the two drugs after 2 weeks of time and assessment period	—

Countries

India

Contacts

Public ContactDr.Aanchal Singh

HAMDARD INSTITUTE OF MEDICAL SCIENCES AND RESEARCH

drarifaanwar@gmail.com9810019911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026